Short-term evaluation of a commercial eyedrop in contact lens wearers (Part 2)

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 30

Inclusion Criteria

1. =18 years of age
2. Adapted and current symptomatic soft CL wearers (i.e. >1 month of wear)
3. Spherical spectacle prescription between +6.00 and -10.00D (inclusive)
4. Correctable to 6/12 (20/40) or better in each eye
5. Require visual correction in both eyes (monovision and multifocal allowed but no monofit)
6. Have normal eyes with no evidence of any ocular abnormality or disease.

Exclusion Criteria

1. Previously shown sensitivity to any of the study solutions’ components.
2. Any systemic or ocular disease or allergies affecting ocular health.
3. Using systemic or topical medications that will, in the investigator’s opinion, affect ocular physiology or lens performance.
4. Clinically significant (>Grade 3) corneal stromal edema, corneal vascularisation, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
5. Any corneal infiltrates or any corneal scarring or neovascularization within the central 5mm of the cornea.
6. Keratoconus or other corneal irregularity.
7. Aphakia or amblyopia.
8. Has diabetes.
9. Known/reported infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
10. History of chronic eye disease (e.g. glaucoma or ARMD).
11. Pregnant or lactating or planning a pregnancy at the time of enrolment.
12. Participation in a concurrent clinical trial or any clinical trial (other than CDRP-402 Part 1) in the last 14 days

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Measured at each of the 4 assessment visits:<br> 1. Subjective comfort [1-100, in 1 unit steps] will be measured using a Visual Analog Scale.<br> 2. Average comfortable wearing time [Hrs:Mins] will be recorded by subjects.<br> 3. Pre-lens Non-invasive break-up time (NIBUT) [s] will be measured using a Keeler Tearscope.<br>

Secondary Outcome Measures

Name	Time	Method
<br> Measured at each of the 4 assessment visits:<br> 1. Subjective dryness [1-100, in 1 unit steps] will be measured using a Visual Analog Scale.<br> 2. Subjective vision quality overall [1-100, in 1 unit steps] will be measured using a Visual Analog Scale.<br> 3. Treatment preference for comfort(1ST/2ND) [LIKERT 1-5] will be measured using a Likert Scale.<br> 4. Ocular health (limbal hyperaemia and corneal staining) will be measured using a slit lamp microscope.<br>

Related Trials